Immunome Appoints Phil Tsai as Chief Technical Officer
27 Junio 2024 - 7:00AM
Business Wire
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused
on developing first-in-class and best-in-class targeted cancer
therapies, today announced the appointment of Phil Tsai, PhD, as
Chief Technical Officer. Dr. Tsai has nearly three decades of
experience in product development, process optimization, and
manufacturing, particularly in the area of antibody-drug conjugates
(ADCs).
“Immunome is excited to add Phil to our management team as we
advance our pipeline of differentiated targeted cancer therapies,”
stated Clay Siegall, PhD, President and Chief Executive Officer of
Immunome. “With the Phase 3 trial of AL102 for the treatment of
desmoid tumors fully enrolled, two IND filings planned for the
first quarter of 2025, and additional ADCs in preclinical
development, Phil’s technical expertise and leadership will greatly
contribute to Immunome’s mission of improving the lives of cancer
patients.”
“I am honored to join Immunome as the company continues to
expand its portfolio and capabilities,” said Dr. Tsai. “Immunome’s
multi-modality approach, combined with its commitment to
underexplored targets, provides exciting opportunities to deliver
best-in-class and first-in-class therapies, and I look forward to
supporting those advancements.”
Prior to joining Immunome, Dr. Tsai spent 21 years at Seagen and
then Pfizer (following the acquisition of Seagen in December 2023)
in positions of increasing responsibility. Most recently, he was
the SVP of Technical Development, responsible for end-to-end
development of biologics and drug-linker manufacturing processes,
analytics, and drug products. Over the past two decades, he led a
productive CMC development organization to advance Seagen’s
pipeline, including commercialization of its products. Dr. Tsai
began his biotech career at Biogen, where he spent seven years
optimizing biologics manufacturing processes.
Dr. Tsai earned his M.S. degree and a PhD in Chemical
Engineering with a minor in Biology from California Institute of
Technology and a B.S. degree from the University of Illinois,
Champaign Urbana.
About Immunome, Inc.
Immunome is a biotechnology company dedicated to developing
first-in-class and best-in-class targeted cancer therapies. Our
portfolio pursues each target with a modality appropriate to its
biology, including small molecules, ADCs, and RLTs. We believe that
pursuing underexplored targets with appropriate drug modalities
leads to transformative therapies. Our proprietary memory B cell
hybridoma technology allows for the rapid screening and functional
characterization of novel antibodies and targets.
For more information, visit www.immunome.com or follow us on
Twitter and LinkedIn.
Cautionary Statement Regarding Forward-Looking
Statements
Certain statements contained in this communication regarding
matters that are not historical facts, are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995 (the “PSLRA”). We use words such as
“excited,” “planned,” “will,” “mission,” “commitment,” “exciting,”
“opportunities,” “look,” “forward,” and similar expressions to
identify these forward-looking statements that are intended to be
covered by the safe-harbor provisions of the PSLRA. These
forward-looking statements include, but are not limited to,
Immunome’s plans to advance its pipeline; expectation to advance
the Phase 3 trial of AL102; expectation for submitting INDs for two
programs; growing its ADC toolbox; achieving its mission;
delivering best-in-class and first-in-class therapeutics; and other
statements regarding management’s intentions, plans, beliefs,
expectations or forecasts for the future. No forward-looking
statement can be guaranteed, and actual results may differ
materially from those projected. These forward-looking statements
are based on Immunome’s expectations and involve risks and
uncertainties; consequently, actual results may differ materially
from those expressed or implied in the statements due to a number
of factors, including, but not limited to, the risk that Immunome
will not be able to realize the benefits of its strategic
transactions; Immunome’s ability to grow and successfully execute
on its business plan, including the development and
commercialization of its pipeline and integration of newly acquired
assets; changes in the applicable laws or regulations; the
possibility that Immunome may be adversely affected by other
economic, business, and/or competitive factors; the risk that
regulatory approvals for Immunome’s programs and product candidates
are not obtained, are delayed or are subject to unanticipated
conditions; the risk that pre-clinical data may not be predictive
of clinical data; the risk that interim results of a clinical trial
do not necessarily predict final results; potential delays in the
commencement, enrollment and completion of clinical trials and the
reporting of data therefrom; the risk that Immunome’s product
candidates and development candidates fail to achieve their
intended endpoints; the complexity of numerous regulatory and legal
requirements that Immunome needs to comply with to operate its
business; the reliance on Immunome’s management; the prior
experience and successes of the Immunome’s management team not
being indicative of any future success; uncertainties related to
Immunome’s capital requirements and Immunome’s expected cash
runway; the failure to obtain, adequately protect, maintain or
enforce Immunome’s intellectual property rights; and other risks
and uncertainties indicated from time to time described in
Immunome’s Annual Report on Form 10-K for the year ended December
31, 2023, filed with the SEC on March 26, 2024, in Immunome’s
Quarterly Report on Form 10-Q for the quarter ended March 31, 2024,
filed with the SEC on May 14, 2024, and in Immunome’s other filings
with the SEC. Immunome cautions that the foregoing list of factors
is not exclusive and not to place undue reliance upon any
forward-looking statements which speak only as of the date made.
Moreover, Immunome operates in a very competitive and rapidly
changing environment. New risks emerge from time to time. Except as
required by law, Immunome does not undertake any obligation to
update publicly any forward-looking statements for any reason after
the date of this press release to conform these statements to
actual results or to changes in their expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240627833859/en/
Investor Contact Max Rosett Chief Financial Officer
investors@immunome.com
Immunome (NASDAQ:IMNM)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Immunome (NASDAQ:IMNM)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024